Fig. 6.

CP5V is a potent inhibitor that suppresses breast tumor progression with no toxicity in the 4T1 xenograft model. (a) CP5V can efficiently cause degradation of Cdc20 in 4T1 cells lines in vitro. (b-e) CP5V dramatically inhibits tumor growth. 4T1 cells were implanted into the mammary fat pad of BALB/c mice. Drug treatment started on the 10th day. Placebo or CP5V at the dose of 100 mg/kg was administrated twice a week for two weeks. (b) The image of 4T1 xenograft tumors harvested after 21 days. (c) Western blotting assays the expression of Cdc20 in 4T1 xenograft tumor. (d) Body weight curve of mice. (e) Tumor growth curve. Tumor volume was measured twice a week. The asterisk represents the significant difference (p-value < 0.05) between group Placebo and group CP5V. (f) Tumor weight curve. (g) Immunohistochemistry Staining of H & E, Cdc20, Ki67, and activated caspase 3 in 4T1 xenograft tumors. Scale bar, 50 μm. (h) H & E staining of tumor and liver of mice from both Placebo and CP5V group. (i) Quantification of Ki67 and activated caspase 3 positive cells in 4T1 xenograft tumors. Data are mean ± SEM.